The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a stakeholder impact survey regarding proposed changes to the pre-market regulations for medical devices and in vitro diagnostics (IVDs) in Great Britain. This survey aims to gather critical insights from industry professionals to inform a comprehensive impact assessment, with a submission deadline set for 11:59 PM on Friday, June 19, 2026.
As the regulatory landscape evolves, the MHRA’s proactive approach underscores the importance of stakeholder engagement in shaping effective policies. By soliciting input from various sectors, including regulatory affairs, quality assurance, and supply chain management, the agency aims to ensure that the new regulations are both practical and beneficial to all parties involved.
The implications of these regulatory changes could be significant for stakeholders across the pharmaceutical and medical device industries. Enhanced regulations may lead to improved safety and efficacy standards, but they could also introduce new compliance challenges and impact timelines for product development and market entry.
Open the full market picture for your next decision →
